257 related articles for article (PubMed ID: 24008659)
1. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.
Nouso K; Miyahara K; Uchida D; Kuwaki K; Izumi N; Omata M; Ichida T; Kudo M; Ku Y; Kokudo N; Sakamoto M; Nakashima O; Takayama T; Matsui O; Matsuyama Y; Yamamoto K;
Br J Cancer; 2013 Oct; 109(7):1904-7. PubMed ID: 24008659
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
Kim BK; Park JY; Choi HJ; Kim DY; Ahn SH; Kim JK; Lee DY; Lee KH; Han KH
J Cancer Res Clin Oncol; 2011 Apr; 137(4):659-67. PubMed ID: 20552225
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
4. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
Song MJ; Bae SH; Chun HJ; Choi JY; Yoon SK; Park JY; Han KH; Kim YS; Yim HJ; Um SH; Chung WJ; Hwang JS; Cho SB; Eun JR
Cancer Chemother Pharmacol; 2015 Apr; 75(4):739-46. PubMed ID: 25663125
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.
Ikeda M; Okusaka T; Sato Y; Furuse J; Mitsunaga S; Ueno H; Morizane C; Inaba Y; Kobayashi T; Arai Y
Jpn J Clin Oncol; 2017 Jun; 47(6):512-519. PubMed ID: 28334948
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
Tsai WL; Lai KH; Liang HL; Hsu PI; Chan HH; Chen WC; Yu HC; Tsay FW; Wang HM; Tsai HC; Cheng JS
PLoS One; 2014; 9(5):e92784. PubMed ID: 24824520
[TBL] [Abstract][Full Text] [Related]
8. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Woo HY; Bae SH; Park JY; Han KH; Chun HJ; Choi BG; Im HU; Choi JY; Yoon SK; Cheong JY; Cho SW; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
Cancer Chemother Pharmacol; 2010 Jan; 65(2):373-82. PubMed ID: 19763572
[TBL] [Abstract][Full Text] [Related]
9. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251
[TBL] [Abstract][Full Text] [Related]
10. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
Lee BH; Lee DS; Cho CW; Yun SS
World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Ueshima K; Kudo M; Takita M; Nagai T; Tatsumi C; Ueda T; Kitai S; Ishikawa E; Yada N; Inoue T; Hagiwara S; Minami Y; Chung H
Oncology; 2010 Jul; 78 Suppl 1():148-53. PubMed ID: 20616598
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
Kuramoto K; Beppu T; Nitta H; Imai K; Masuda T; Miyata T; Koga Y; Kitano Y; Kaida T; Nakagawa S; Okabe H; Hayashi H; Hashimoto D; Yamashita YI; Chikamoto A; Kikuchi K; Baba H
Anticancer Res; 2018 Jan; 38(1):525-531. PubMed ID: 29277819
[TBL] [Abstract][Full Text] [Related]
15. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
[TBL] [Abstract][Full Text] [Related]
16. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
[TBL] [Abstract][Full Text] [Related]
17. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
[TBL] [Abstract][Full Text] [Related]
18. [Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
Osuga K; Murakami T; Nakata S; Tomoda K; Nagano H; Monden M; Nakamura H
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2114-7. PubMed ID: 15628754
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Oh MJ; Lee HJ; Lee SH
Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
